These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 37149685)

  • 21. Chronic Vascular Arrest as a Predictor of Bevacizumab Treatment Failure in Retinopathy of Prematurity.
    Toy BC; Schachar IH; Tan GS; Moshfeghi DM
    Ophthalmology; 2016 Oct; 123(10):2166-75. PubMed ID: 27506484
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors associated with refractive outcome in children treated with bevacizumab for retinopathy of prematurity: the importance of retinal vascularization.
    Bayramoglu SE; Sayin N
    Int Ophthalmol; 2022 Oct; 42(10):3199-3210. PubMed ID: 35579771
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes of early versus deferred laser after intravitreal ranibizumab in aggressive posterior retinopathy of prematurity.
    Gangwe AB; Agrawal D; Gangrade AK; Parchand SM; Agrawal D; Azad RV
    Indian J Ophthalmol; 2021 Aug; 69(8):2171-2176. PubMed ID: 34304203
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison in Retreatments between Bevacizumab and Ranibizumab Intravitreal Injections for Retinopathy of Prematurity: A Multicenter Study.
    Patel NA; Acaba-Berrocal LA; Hoyek S; Fan KC; Martinez-Castellanos MA; Baumal CR; Harper CA; Berrocal AM;
    Ophthalmology; 2023 Apr; 130(4):373-378. PubMed ID: 36396121
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediction of visual outcomes by an artificial neural network following intravitreal injection and laser therapy for retinopathy of prematurity.
    Huang CY; Kuo RJ; Li CH; Ting DS; Kang EY; Lai CC; Tseng HJ; Yang LY; Wu WC
    Br J Ophthalmol; 2020 Sep; 104(9):1277-1282. PubMed ID: 31744795
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment outcomes of combination of anti-vascular endothelial growth factor injection and laser photocoagulation in Type 1 ROP and APROP.
    Sen P; Agarwal AAK; Bhende P; Ganesan S
    Int Ophthalmol; 2022 Jan; 42(1):95-101. PubMed ID: 34415476
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravitreal bevacizumab for retinopathy of prematurity: refractive error results.
    Harder BC; Schlichtenbrede FC; von Baltz S; Jendritza W; Jendritza B; Jonas JB
    Am J Ophthalmol; 2013 Jun; 155(6):1119-1124.e1. PubMed ID: 23490192
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aggressive posterior retinopathy of prematurity in two cohorts of patients in South India: implications for primary, secondary, and tertiary prevention.
    Shah PK; Subramanian P; Venkatapathy N; Chan RVP; Chiang MF; Campbell JP
    J AAPOS; 2019 Oct; 23(5):264.e1-264.e4. PubMed ID: 31521847
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FIVE-YEAR VISUAL OUTCOME OF TREATMENT FOR RETINOPATHY OF PREMATURITY IN INFANTS WEIGHING <500 G AT BIRTH: A Multicenter Cohort Study From J-CREST.
    Tomioka M; Murakami T; Okamoto F; Kinoshita T; Shinomiya K; Nishi T; Jujo T; Obata S; Tsukitome H; Ogura S; Ueda K; Ishii R; Oshika T
    Retina; 2024 Apr; 44(4):652-658. PubMed ID: 38064668
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II.
    Autrata R; Krejcírová I; Senková K; Holoušová M; Doležel Z; Borek I
    Eur J Ophthalmol; 2012; 22(5):687-94. PubMed ID: 22669848
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anatomical and refractive outcomes in patients with treated retinopathy of prematurity.
    Lolas M; Tuma A; Zanolli M; Agurto R; Stevenson R; Ossandón D
    Arch Soc Esp Oftalmol; 2017 Oct; 92(10):472-476. PubMed ID: 28624314
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Primary and additional treatment preference in aggressive retinopathy of prematurity and type 1 retinopathy of prematurity.
    Jang JH; Kang YK; Park HS; Kim K; Kim SS; Han JY; Kim HW; Bang JW; Song JS; Park SJ; Woo SJ; Joo KS; Yoo WS; Chung I; Cho YW; Lee JH; Choi HJ; Chung YR
    BMJ Open Ophthalmol; 2023 Jan; 8(1):. PubMed ID: 37278416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years: part 1. Visual function and structural outcome.
    Ng EY; Connolly BP; McNamara JA; Regillo CD; Vander JF; Tasman W
    Ophthalmology; 2002 May; 109(5):928-34; discussion 935. PubMed ID: 11986099
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity.
    Karkhaneh R; Khodabande A; Riazi-Eafahani M; Roohipoor R; Ghassemi F; Imani M; Dastjani Farahani A; Ebrahimi Adib N; Torabi H
    Acta Ophthalmol; 2016 Sep; 94(6):e417-20. PubMed ID: 27009449
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treated threshold stage 3 versus spontaneously regressed subthreshold stage 3 retinopathy of prematurity: a study of motility, refractive, and anatomical outcomes at 6 months and 36 months.
    Sahni J; Subhedar NV; Clark D
    Br J Ophthalmol; 2005 Feb; 89(2):154-9. PubMed ID: 15665344
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ocular complications following treatment in the Postnatal Growth and Retinopathy of Prematurity (G-ROP) Study.
    Morrison D; Shaffer J; Ying GS; Binenbaum G;
    J AAPOS; 2018 Apr; 22(2):128-133. PubMed ID: 29548840
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Study protocol for prognosis and treatment strategy of peripheral persistent avascular retina after intravitreal anti-VEGF therapy in retinopathy of prematurity.
    Yu Y; Wang J; Chen F; Chen W; Jiang N; Xiang D
    Trials; 2020 Jun; 21(1):493. PubMed ID: 32513245
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Argon laser photocoagulation for retinopathy of prematurity: long-term outcome.
    Ospina LH; Lyons CJ; Matsuba C; Jan J; McCormick AQ
    Eye (Lond); 2005 Nov; 19(11):1213-8. PubMed ID: 15543189
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of refractive error in children treated for retinopathy of prematurity with anti-vascular endothelial growth factor (anti-VEGF) agents: A meta-analysis and systematic review.
    Tan QQ; Christiansen SP; Wang J
    PLoS One; 2019; 14(12):e0225643. PubMed ID: 31790445
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravitreal Bevacizumab for Zone II Retinopathy of Prematurity.
    Larrañaga-Fragoso P; Peralta J; Bravo-Ljubetic L; Pastora N; Abelairas-Gómez J
    J Pediatr Ophthalmol Strabismus; 2016 Nov; 53(6):375-382. PubMed ID: 27537247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.